Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial

Denis Roy, Craig M. Pratt, Christian Torp-Pedersen, D. George Wyse, Egon Toft, Steen Juul-Moller, Tonny Nielsen, S. Lind Rasmussen, Ian G. Stiell, Benoit Coutu, John H. Ip, Edward L C Pritchett, A. John Camm

Research output: Contribution to journalArticlepeer-review

291 Scopus citations


BACKGROUND - The present study assessed the efficacy and safety of vernakalant hydrochloride (RSD1235), a novel compound, for the conversion of atrial fibrillation (AF). METHODS AND RESULTS - Patients were randomized in a 2:1 ratio to receive vernakalant or placebo and were stratified by AF duration of 3 hours to 7 days (short duration) and 8 to 45 days (long duration). A first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes, followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if AF was not terminated. The primary end point was conversion of AF to sinus rhythm for at least 1 minute within 90 minutes of the start of drug infusion in the short-duration AF group. A total of 336 patients were randomized and received treatment (short duration, n=220; long duration, n=116). Of the 145 vernakalant patients, 75 (51.7%) in the short-duration AF group converted to sinus rhythm (median time, 11 minutes) compared with 3 of the 75 placebo patients (4.0%; P<0.001). Overall, in the short- and long-duration AF groups, 83 of the 221 vernakalant patients (37.6%) experienced termination of AF compared with 3 of the 115 placebo patients (2.6%; P<0.001). Transient dysgeusia and sneezing were the most common side effects in vernakalant-treated patients. Four vernakalant-related serious adverse events (hypotension [2 events], complete atrioventricular block, and cardiogenic shock) occurred in 3 patients. CONCLUSION - Vernakalant demonstrated rapid conversion of short-duration AF and was well tolerated.

Original languageEnglish (US)
Pages (from-to)1518-1525
Number of pages8
Issue number12
StatePublished - Mar 2008


  • Antiarrhythmia agents
  • Arrhythmia
  • Fibrillation
  • Vernakalant

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this